• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Goodbye 2022—The Top 10 Biosimilars Stories of the Year


To say goodbye to 2022 and welcome in the new year, The Center for Biosimilars recaps the biggest news stories and milestones from the past 12 months as well as list of the top 5 podcast episodes of the year.

On this episode, we’re going to review the top stories and milestones to hit the biosimilar industry this year. From the launch of a generic lenalidomide, the FDA approval of a high-concentration adalimumab biosimilar, to the launch of the first ophthalmology biosimilar. We’re also going to be recommending our top 5 podcast episodes of the year so stick around to hear more about what 2022 has in store for biosimilars around the world.

Show notes

Top 10 stories of the year:

10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar

9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA

8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023

7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology

6. Report: Biosimilar Competition in Europe

5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options

4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira

3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab

2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar

1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid

Top 5 podcast episodes of the year:

5. How Health Policy Can Impact Adoption for Adalimumab Biosimilars

4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar

3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market

1. What Will Year 1 Look Like for Adalimumab Biosimilars?

Recent Videos
Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Related Content
© 2024 MJH Life Sciences

All rights reserved.